"Guide" of muscone modification enhanced brain-targeting efficacy and anti-glioma effect of lactoferrin modified DTX liposomes.
brain targeting
glioma
lactoferrin
modified liposome
muscone
Journal
Bioengineering & translational medicine
ISSN: 2380-6761
Titre abrégé: Bioeng Transl Med
Pays: United States
ID NLM: 101689146
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
03
02
2022
revised:
10
05
2022
accepted:
07
06
2022
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
epublish
Résumé
Glioma is one of the most aggressive malignant diseases for human health. It is difficult to resect completely due to their invasiveness. The targeted delivery, as a noninvasive approach, is a major strategy for the development of treatments for brain tumors. Lactoferrin (Lf) receptors are over-expressed in both brain endothelial cells and glioma cells. Macromolecular Lf modified nanoparticles have been shown to enhance the brain targeting. Muscone is a "guide" drug that have been demonstrated to promote liposomes into the brain by modification. To further enhance the brain-targeting efficacy of Lf modified carriers, we designed that Lf and muscone dual-modified liposomes cross blood-brain barrier (BBB) and target to brain for enhanced docetaxel (DTX) brain delivery. The results showed that we successfully prepared Lf and muscone dual-modified liposomes (Lf-LP-Mu-DTX), the number of Lf molecules connected to the surface of per liposome was 28. Lf-LP-Mu-DTX increased uptake in both U87-MG cells and hCMEC/D3 cells, enhanced penetration of U87-MG tumor spheroid and in vitro BBB model, had better in vitro and in vivo anti-tumor effects. In conclusion, "guide" of muscone modification enhanced brain-targeting efficacy of Lf modified liposomes, Lf and muscone dual-modified docetaxel loaded liposomes present a potential brain-targeting drug delivery system for use in the future treatment of gliomas.
Identifiants
pubmed: 36925685
doi: 10.1002/btm2.10393
pii: BTM210393
pmc: PMC10013770
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10393Informations de copyright
© 2022 The Authors. Bioengineering & Translational Medicine published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Theranostics. 2020 Mar 4;10(10):4308-4322
pubmed: 32292496
FASEB J. 2005 Nov;19(13):1872-4
pubmed: 16141364
Mol Pharm. 2014 Jun 2;11(6):1823-34
pubmed: 24779677
Pharm Res. 2014 May;31(5):1275-89
pubmed: 24338512
J Nanobiotechnology. 2021 Jun 23;19(1):188
pubmed: 34162396
Eur J Pharm Sci. 2016 Jun 10;88:178-90
pubmed: 26965003
Biomaterials. 2021 Jul;274:120888
pubmed: 34029915
Pharm Res. 2013 Oct;30(10):2560-72
pubmed: 23615859
ACS Appl Mater Interfaces. 2017 Jun 21;9(24):20410-20416
pubmed: 28541655
Curr Opin Struct Biol. 2017 Aug;45:109-115
pubmed: 28040636
Int J Pharm. 2018 May 30;543(1-2):179-189
pubmed: 29555442
Int J Pharm. 2018 Feb 15;537(1-2):257-267
pubmed: 29294323
Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):17-24
pubmed: 23673491
Biomaterials. 2013 May;34(15):3870-81
pubmed: 23453061
Yao Xue Xue Bao. 2016 Aug;51(8):1245-9
pubmed: 29897726
Pharmacology. 2018;101(5-6):269-277
pubmed: 29502118
Anal Biochem. 1980 May 1;104(1):10-4
pubmed: 6892980
Int J Nanomedicine. 2019 Sep 11;14:7431-7446
pubmed: 31686815
Int J Mol Sci. 2013 Jan 14;14(1):1629-54
pubmed: 23344060
Int J Nanomedicine. 2018 Mar 28;13:1869-1879
pubmed: 29636606
Proteomics. 2016 Dec;16(24):3105-3110
pubmed: 27095603
Eur J Pharm Biopharm. 2005 Jul;60(2):295-303
pubmed: 15939240
Biol Pharm Bull. 2010;33(7):1253-5
pubmed: 20606324
J Neuroimmune Pharmacol. 2017 Mar;12(1):6-16
pubmed: 27270720
Colloids Surf B Biointerfaces. 2018 Dec 1;172:213-223
pubmed: 30172202
Int J Pharm. 2016 Jul 25;509(1-2):431-438
pubmed: 27286634
Int J Pharm. 1999 Feb 1;178(1):33-46
pubmed: 10205623
Int J Pharm. 2012 May 10;427(2):234-41
pubmed: 22349049
J Cereb Blood Flow Metab. 2009 Dec;29(12):1914-23
pubmed: 19654588
Nanotheranostics. 2018 Jan 1;2(1):70-86
pubmed: 29291164
Int J Nanomedicine. 2017 Aug 21;12:6089-6105
pubmed: 28860768
Nat Rev Drug Discov. 2011 Jul 01;10(7):521-35
pubmed: 21720407
ACS Appl Mater Interfaces. 2018 Sep 12;10(36):30201-30213
pubmed: 30113810
Biochim Biophys Acta. 1995 Nov 1;1239(2):133-44
pubmed: 7488618
Int J Pharm. 2013 Nov 1;456(1):73-9
pubmed: 23973509
Front Microbiol. 2017 Jan 18;8:2
pubmed: 28149293
Adv Sci (Weinh). 2021 Feb 24;8(9):2004025
pubmed: 33977060
Oncol Lett. 2014 Nov;8(5):2000-2006
pubmed: 25289086
J Control Release. 2013 Aug 10;169(3):204-10
pubmed: 23388072
Nat Commun. 2017 May 10;8:15144
pubmed: 28489075
Nanomaterials (Basel). 2018 Mar 20;8(3):
pubmed: 29558440
ACS Appl Mater Interfaces. 2016 Nov 9;8(44):29977-29985
pubmed: 27797175
Acta Pharm Sin B. 2016 Jul;6(4):268-86
pubmed: 27471668
Eur J Pharm Sci. 2011 Sep 18;44(1-2):164-73
pubmed: 21782939
Acta Biomater. 2018 Apr 1;70:227-236
pubmed: 29412186
Biomaterials. 2011 Jan;32(2):495-502
pubmed: 20970851
Artif Cells Nanomed Biotechnol. 2018 Nov;46(7):1390-1401
pubmed: 28838252
Cell Mol Neurobiol. 2015 Nov;35(8):1105-15
pubmed: 25976179
Org Biomol Chem. 2017 Mar 8;15(10):2157-2162
pubmed: 28221378
ACS Appl Mater Interfaces. 2019 Jul 31;11(30):26731-26744
pubmed: 31268657
Colloids Surf B Biointerfaces. 2016 May 1;141:260-267
pubmed: 26859117